Select Your Location:
Global
France
Italy

Fast Facts: Waldenström’s Macroglobulinemia (For Patients)

Disease State: Waldenström's macroglobulinemia

Fast Facts: Waldenström's Macroglobulinemia (For Patients)

This book offers the necessary information for patients diagnosed with Waldenström’s macroglobulinemia (WM) to engage in meaningful conversations with their healthcare providers. It empowers them to make informed decisions about managing their condition. Download this e-book to provide your patients with a deeper understanding of their illness.

Reading
26 May 2025
Please login or register to access the download
Alessandra Tedeschi, Giorgio Minotti, Joe-Elie Salem, Stephan Stilgenbauer

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video
26 May 2025
Clemens Wendtner, Renata Walewska, Pier Luigi Zinzani, Matthew Davids

Overview of the treatment options for treatment naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and the use of BTKis in indolent lymphomas presented at the EHA2024 Hybrid Congress.

Video
26 May 2025

A global congress digest on targeted therapies in B-cell malignancies covering updates from recent studies presented at EHA2024.

Reading
26 May 2025
Please login or register to access the download

ASPEN (NCT03053440) is an open-label, randomized, Phase 3 study comparing the safety, efficacy and clinical benefit of zanubrutinib versus ibrutinib in activating MYD88 mutated (MYD88MUT) Waldenström’s macroglobulinemia (WM) patients. In an additional cohort, the efficacy and safety of zanubrutinib in MYD88 wild-type (MYD88WT) WM patients were evaluated.

Reading
23 May 2025